You are here: Home > Institute of Excellence (CPD) > Calendar > CPD Events > A new option in the treatment of AMD – postponed

A new option in the treatment of AMD

Date: 17/03/2020

Venue: Bundaberg Eye Clinic, 302 Bourbong St, Bundaberg , QLD, 4670

Provider: Inservio- change it as required

Contact: Justine Cant, [E] justine.cant@inservio.com.au, [P] 0425600318

Learning Objectives

  • Participants will receive an introduction to Beovu
  • Participants will understand the molecular structure of Beovu
  • Participants will understand the different molecular structures of all current PBS listed treatments for AMD
  • Participants will understand the Beovu Hawk and Harrier trial data
  • Particiapants will be aware of the TGA indication of Beovu
  • Participants will discuss AMD cases based on presentation of OCT and OCTA
  • Participants will understand the use of OCTA in the diagnosis of AMD
  • Particiapants will understand the use of using OCTA in diagnosing preclinical exudative macular degenetation

Max points awarded: 3.34

Session Information

Name
Introdction to Beovu
Activity Type
Face to Face without Assessment
Therapeutic?
No
Manufacturer/Supplier?
No
Points for attending & Passing Assessment
0.67
Name
Beovu as a new option in the treatment of AMD
Activity Type
Face to Face without Assessment
Therapeutic?
No
Manufacturer/Supplier?
No
Points for attending & Passing Assessment
1.00
Name
Case Presentations
Activity Type
Face to Face without Assessment
Therapeutic?
No
Manufacturer/Supplier?
No
Points for attending & Passing Assessment
0.67
Name
Use of OCTA in diagnosis of AMD
Activity Type
Face to Face without Assessment
Therapeutic?
No
Manufacturer/Supplier?
No
Points for attending & Passing Assessment
1.00